Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Recruiting · NCT05491226 · Registry updated 2026-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-04-20 | NCT05491226 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| Merck Sharp & Dohme LLC | 650 |
| Stephen Shiao | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |